Sentences with phrase «school of oncology»

The awards, organised by the European School of Oncology's Cancer World magazine, attracted 145 entries from every corner of the globe.

Not exact matches

The Harvard Business School Kraft Precision Medicine Accelerator is working with the MMRF and other cancer partners to harness the potential of master protocols in precision oncology.

According to Leena Hilakivi - Clarke, professor of oncology at Georgetown University School of Medicine, some women who gained more than 33 pounds during pregnancy had a significantly higher risk of breast cancer than mothers who kept their weight gain between 25 and 32 pounds.

«We're trying to build models that describe how tumors grow and respond to therapy,» said Yankeelov, director of the Center for Computational Oncology at The University of Texas at Austin (UT Austin) and director of Cancer Imaging Research in the LIVESTRONG Cancer Institutes of the Dell Medical School.

«We present an interdisciplinary approach to studying immunotherapy and immune surveillance of tumors,» said Benjamin Greenbaum, PhD, the senior author, who is affiliated with the departments of Medicine, Hematology and Medical Oncology, Pathology, and Oncological Sciences at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

Already, it includes UCR's Jikui Song, an assistant professor of biochemistry, and Dr. Samar Nahas, an assistant clinical professor of gynecology and oncology in the School of Medicine.

However, the majority of patients develop treatment - resistant tumors, and only 10 to 15 percent of these patients survive long term, says Ie - Ming Shih, M.D., Ph.D., the Richard W. TeLinde Distinguished Professor in the department of Gynecology and Obstetrics, who led the study with Tian - Li Wang, Ph.D., an associate professor of pathology and oncology at the Johns Hopkins University School of Medicine.

The protein puts the immune system's brakes on, keeping its T cells from recognizing and attacking cancer cells, said Dr. Antoni Ribas, the study's principal investigator and a professor of medicine in the division of hematology - oncology at the David Geffen School of Medicine at UCLA.

«These results suggest that biology is not as deterministic as many scientists think,» says Andrew Feinberg, M.D., M.P.H., the King Fahd Professor of Medicine, Oncology, and Molecular Biology and Genetics at the Johns Hopkins University School of Medicine and director of the Center for Epigenetics in the Institute for Basic Biomedical Sciences.

«Patients diagnosed with early - stage prostate cancer — and that's the vast majority of patients with this disease — face many treatment options that are thought to be similarly efficacious,» said Ronald C. Chen, MD, MPH, UNC Lineberger member and associate professor in the UNC School of Medicine Department of Radiation Oncology.

Physician - scientists at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine presented their findings and strategies to increase rates on March 13 at the Society of Surgical Oncology Cancer Symposium in Phoenix.

«Estimating from various studies that looked at increasing BMI and endometrial cancer risk, a woman with a Body Mass Index (BMI) of 40 would have approximately eight times greater risk of endometrial cancer than someone with a BMI of 25,» said first author Kristy Ward, MD, the senior gynecologic oncology fellow in the Department of Reproductive Medicine at UC San Diego School of Medicine.

Professor Paolo Boffetta (MD), the Annals of Oncology associate editor for epidemiology and Director of the Institute of Translational Epidemiology at the Icahn School of Medicine at Mount Sinai in New York (USA), commented: «These results are extremely important in showing that reducing cancer mortality can be achieved: priority should be given to research in cancers with unfavourable trends, such as pancreatic cancer, and in reducing cancer mortality disparities, both between countries (Central / Eastern versus Western Europe), and within countries, for example, between socioeconomic groups.

«Our analysis found that the lowest satisfaction scores were obtained from population - dense regions of Washington, DC; New York State, California, Maryland and New Jersey, and the best scores were from Louisiana, South Dakota, Iowa, Maine and Vermont,» said senior author Randall Holcombe, MD, Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, and Chief Medical Officer for Cancer for The Mount Sinai Health System.

«Our preclinical data suggest that combining low doses of these inhibitors will enhance the clinical effects of both drugs as a potential treatment for patients with AML,» says the senior author, Feyruz V. Rassool, PhD, associate professor of radiation oncology at the University of Maryland School of Medicine (UM SOM) and a researcher at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC).

«Across the country, large hospital size and non-English as a primary language predicted poor patient satisfaction scores while white race and higher education level predicted better scores,» said co-author Daniel McFarland, DO, Clinical Fellow, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai.

If not, then we probably shouldn't be using it,» says Nita Ahuja, M.D., an associate professor of surgery and oncology at the Johns Hopkins University School of Medicine and leader of the study published online on Dec. 18 in JAMA Surgery.

«This is not positive news for astronauts deployed on a two - to - three - year round trip to Mars,» said the professor of radiation oncology in UCI's School of Medicine.

Young people with body mass indexes (BMIs) over 30 are more likely to experience aggressive malignancies, says author Nathan A. Berger, MD, Hanna - Payne Professor of Experimental Medicine; director of the Center for Science, Health and Society; member of the Case Comprehensive Cancer Center; and professor of medicine, biochemistry, oncology and genetics at Case Western Reserve University School of Medicine.

«It was kind of fun being at a medical school and known as the weird guy who worked with dogs,» says Modiano, who is now a professor of comparative oncology at the University of Minnesota College of Veterinary Medicine and the Masonic Cancer Center, where his research focuses on immunology, cancer cell biology, cancer genetics, and applications of gene therapy.

Future studies are planned by Chang and other School of Medicine researchers — including senior author Kenneth R. Carson, MD, PhD, an assistant professor of oncology, and Graham Colditz, MD, DrPH, a cancer expert who also is associate director of prevention and control at Siteman Cancer Center at Washington University School of Medicine and Barnes - Jewish Hospital.

Often, it is not diagnosed until at a late stage, when many tumors have already formed,» said principal investigator Lucian Chirieac, MD, a thoracic oncology pathologist in the Department of Pathology at BWH and associate professor at Harvard Medical School.

To ensure that patients can receive all recommended care, we need to recognize the financial burden of cancer and identify patients at risk for financial concerns,» says lead study author Christine M. Veenstra, M.D., M.S.H.P., clinical lecturer in hematology / oncology at the University of Michigan Medical School.

«If you're going to use an MRI scan or a CT scan or... do something like radiosurgery, you need a team of people, because nobody has the expertise to span neurosurgery, the medical portion of radiation oncology, and medical physics,» says Frank Bova, professor of neurosurgery at the University of Florida medical school in Gainesville.

Division of Biostatistics and Bioinformatics, Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine and Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, 550 North Broadway, Baltimore, MD 21205, USA.

«This study opens the door for combination therapy with BRAF inhibitors and autophagy inhibitors, which haven't been explored deeply as a therapeutic option for patients whose tumors are resistant,» said Ravi K. Amaravadi, MD, assistant professor of Medicine in the division of Hematology / Oncology at the Perelman School of Medicine and co-leader of the Cancer Therapeutics Program at Penn Medicine's Abramson Cancer Center.

This is the first study to show the role that type I interferon plays in driving the body's immune destruction during HIV infection, said Scott Kitchen, associate professor of medicine in the division of hematology / oncology at the David Geffen School of Medicine at UCLA and senior author of the study published in the peer - reviewed Journal of Clinical Investigation.

Location was another reason for choosing the Translational Oncology Laboratory at Barts and The London Queen Mary's School of Medicine and Dentistry.

Stem Cell Program, Division of Hematology and Oncology, Pediatric Hematology Program, Boston Children's Hospital and Dana - Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

«While tumor profiling holds the promise of improved therapeutics through personalized medicine, it is important that both clinicians and patients discuss the possibilities of incidental findings prior to ordering the testing, as the findings can have serious implications for both the patient and their family members,» said Melinda Yushak, M.D., M.P.H., first author on the study and a medical oncology fellow in Yale School of Medicine.

Principal investigator Leena Gandhi, MD, PhD, director of the thoracic medical oncology program at Perlmutter Cancer Center at NYU Langone Health and associate professor of Medicine in the division of Medical Oncology at NYU School of Medicine, presented these findings April 16 at the American Association for Cancer Research (AACR) Annual Meeting 2018 in oncology program at Perlmutter Cancer Center at NYU Langone Health and associate professor of Medicine in the division of Medical Oncology at NYU School of Medicine, presented these findings April 16 at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Oncology at NYU School of Medicine, presented these findings April 16 at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago.

Naomi Ko, MD, MPH, instructor of medicine in the Section of Hematology Oncology at Boston University School of Medicine and a practicing breast oncologist at Boston Medical Center, stresses the need for further investigation.

«We wondered whether we could make a safer and more tolerable form of DON by enhancing its brain penetration and limiting its exposure to the rest of the body and, thus, toxicity,» says Barbara Slusher, Ph.D., professor of neurology, medicine, psychiatry, neuroscience and oncology at the Johns Hopkins University School of Medicine and director of Johns Hopkins Drug Discovery.

said UNC Lineberger's Stergios Moschos, MD, an associate professor in the UNC School of Medicine Department of Hematology / Oncology and a co-author of the study.

Jean - Pierre Issa, MD, Director of the Fels Institute for Cancer Research and Molecular Biology at Temple University School of Medicine and co-Leader of the Cancer Epigenetics Program at the Fox Chase Cancer Center is lead author of the study, which has been published August 19 in the journal, Lancet Oncology.

In men whose prostate cancer spreads, doctors typically prescribe drugs that block testosterone production, but cancer cells eventually become resistant to this means of reducing the hormone, says Denmeade, a professor of oncology at the Johns Hopkins University School of Medicine.

The tumors» genomes were then analyzed for genetic mutations, or alterations in their DNA, by her team and that of Bert Vogelstein, M.D., professor of oncology at the Johns Hopkins University School of Medicine and the co-director of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center.

In addition, the subgroup of patients with unmethylated MGMT promoter and HLA - A2 appear to particularly benefit,» said Patrick Y. Wen, MD, director of the Center for Neuro - Oncology at Dana - Farber Cancer Institute and professor of Neurology, Harvard Medical School, who will present the data at the conference.

«For someone to go up against alectinib, it would be nice to know earlier if there might be an improvement,» says Robert C. Doebele, MD, PhD, investigator at the University of Colorado Cancer Center and associate professor of Medical Oncology at the CU School of Medicine.

Stewart Massad is chief of the gynecologic oncology division at the Southern Illinois University School of Medicine in Springfield.

As of 1991, Dr. Jain is the Andrew Werk Cook Professor of Tumor Biology (Radiation Oncology) at Harvard Medical School, and director of the Edwin L. Steele Laboratory of Tumor Biology at Massachusetts General Hospital.

However, some of these cancers become resistant to the effects of radiation over time, according to Venu Raman, Ph.D., an associate professor of radiology and radiological science and of oncology at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center.

«We are planning clinical trials with a recently developed vaccine to target annexin A2,» says Zheng, an associate professor of oncology and surgery at the Johns Hopkins University School of Medicine.

Co-investigators on the study are Vancheswaran Gopalakrishnan, doctoral student at The University of Texas Health Science Center at Houston School of Public Health; Christine Spencer, Tatiana Karpinets, Ph.D., Robert Jenq, M.D., and Andrew Futreal, Ph.D., of Genomic Medicine; Miles Cameron Andrews, Ph.D., Alexandre Reuben, Ph.D., Jeffrey Lee, M.D., and Jeffrey Gershenwald, M.D., of Surgical Oncology; Michael Tetzlaff, Ph.D., M.D., and Alexander Lazar, M.D., Ph.D., of Pathology; Wen - Jen Hwu, M.D., Ph.D., Claudia Glitza, M.D., Ph.D., Hussein Tawbi, M.D., Ph.D., Sapna Patel, M.D., Michael Davies, M.D., Ph.D., and Patrick Hwu, M.D., of Melanoma Medical Oncology; Padmanee Sharma, M.D., Ph.D., of Genitourinary Medical Oncology and Immunology; and Jim Allison, Ph.D., of Immunology.

«The link between metabolism and cancer has been proposed or inferred to exist for a long time, but what is more scarce is evidence for a direct connection — genetic mutations in metabolic enzymes,» said senior author Ricardo C.T. Aguiar, M.D., Ph.D., associate professor of hematology - oncology in the School of Medicine and a faculty scientist with the Cancer Therapy & Research Center (CTRC) at the UT Health Science Center and the South Texas Veterans Health Care System, Audie L. Murphy Division.

Ross is the Roger A. Berg Research Professor of radiology and professor of biological chemistry at the U-M Medical School, while Rehemtulla is the Ruth Tuttle Freeman Research Professor of Radiation Oncology.

«Even before the patient completes all of the MRIs, CT scans and other imaging procedures following diagnosis, we can have a recommendation for which drug and dosage to prescribe,» said Kareem Azab, PhD, an assistant professor of radiation oncology at the School of Medicine and the Siteman Cancer Center member who leads the research.

«This is the first national study to identify specific regions of the United States where residents may be at an increased risk for poor clinical outcomes — including misdiagnoses and late detection — as a result of limited access to specialized gynecologic cancer care,» says David Shalowitz, MD, a fellow in the division of Gynecologic Oncology at the Perelman School of Medicine at the University of Pennsylvania, and lead author on the study.

Teeth and nails are good for measuring radiation because they pick up free radicals (atoms, or ions, with unpaired electrons) created by ionizing radiation and can retain them for long periods of time, says Harold Swartz, a Dartmouth Medical School professor of radiation oncology and director of the Dartmouth Biodosimetry Center for Medical Countermeasures against Radiation.

Jain is the Cook Professor of Radiation Oncology (Tumor Biology) at Harvard Medical School.